Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Oncotelic Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Oncotelic Accesses Rapid IND Development Platform Through Partnership with Medicilon
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Oncotelic Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Medicilon & Hengrui Pharma Deepen Collaboration on ADCs, Small Nucleic Acids, & CGT Drugs
Details :
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Undisclosed
Deal Type : Collaboration